Curium Receives Marketing Authorization in the EU for PYLCLARI™, an Innovative 18F-PSMA PET Tracer Indicated in Adults With Prostate Cancer
Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium, commented, “We are very pleased to receive marketing authorization in the EU for PYLCLARI™.
- Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium, commented, “We are very pleased to receive marketing authorization in the EU for PYLCLARI™.
- The successful clinical development and granted marketing authorization of PYLCLARI™ in the EU confirms our mission to redefine the experience of cancer through our trusted legacy in nuclear medicine.
- When in full production, PYLCLARI™ will be the most widely available 18F-PSMA tracer in Europe.
- In the U.S., Lantheus received approval for [18F]-DCFPyL, now PYLARIFY® (Piflufolastat F 18 Injection) from the Food and Drug Administration (FDA) in May 2021.